NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 125 (carbidopa, levodopa, and entacapone) by Orion Pharma is dopa decarboxylase inhibitors [moa]. Approved for aromatic amino acid decarboxylation inhibitor [epc]. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 125 is an oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works by inhibiting DOPA decarboxylase and catechol-O-methyltransferase to enhance dopamine availability in the brain. This combination therapy extends levodopa efficacy and reduces motor fluctuations in mid-stage Parkinson's patients.
$0.031BPart D
LOE ApproachingDeclining
Low spending ($31K in 2023) with 14 claims signals a mature, niche product with minimal team expansion opportunities; positions suited for legacy brand management or transition planning.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Career Relevance
Working on STALEVO 125 offers limited growth trajectory; roles focus on defending market share, managing LOE transition, and supporting generic conversion. Ideal for early-to-mid career pharma professionals seeking mature product management experience rather than launch excitement or expansion.
Worked on STALEVO 125 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.